No­var­tis takes next step in Rus­sia, halt­ing new tri­als and en­roll­ment as Big Phar­ma re­sponds to Ukraine in­va­sion

Af­ter No­var­tis an­nounced it was trim­ming down some of its busi­ness ac­tiv­i­ties in Rus­sia, the glob­al phar­ma is tak­ing the next step — and this time, it’s more in lock­step with oth­er com­pa­nies in the in­dus­try.

The phar­ma re­leased a state­ment ear­ly Wednes­day, and while most of it has al­ready been pre­vi­ous­ly cov­ered by End­points News, this is in­ter­est­ing to note:

We have im­ple­ment­ed a pack­age of mea­sures that in­clude sus­pend­ing cap­i­tal in­vest­ments, me­dia ad­ver­tis­ing, and oth­er pro­mo­tion­al ac­tiv­i­ties in Rus­sia. In ad­di­tion to that, while we re­main com­mit­ted to pro­vide ac­cess to our med­i­cine in Rus­sia, we re­spon­si­bly pause the ini­ti­a­tion of new clin­i­cal tri­als and the en­roll­ment of new study par­tic­i­pants in ex­ist­ing tri­als. These mea­sures will be kept un­der re­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER